Peddock Capital Advisors LLC Grows Stake in Allergan plc (NYSE:AGN)

Peddock Capital Advisors LLC raised its holdings in shares of Allergan plc (NYSE:AGN) by 13.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 2,724 shares of the company’s stock after purchasing an additional 326 shares during the quarter. Peddock Capital Advisors LLC’s holdings in Allergan were worth $399,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in AGN. Oregon Public Employees Retirement Fund grew its holdings in shares of Allergan by 14,208.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock worth $155,000 after buying an additional 20,617,639 shares in the last quarter. Longview Partners Guernsey LTD boosted its position in shares of Allergan by 288.6% during the 4th quarter. Longview Partners Guernsey LTD now owns 6,026,108 shares of the company’s stock valued at $805,450,000 after acquiring an additional 4,475,447 shares during the last quarter. Norges Bank acquired a new position in shares of Allergan during the 4th quarter valued at about $484,853,000. Janus Henderson Group PLC boosted its position in shares of Allergan by 27.6% during the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after acquiring an additional 1,265,742 shares during the last quarter. Finally, Ellis Investment Partners LLC boosted its position in shares of Allergan by 14,302.8% during the 1st quarter. Ellis Investment Partners LLC now owns 852,214 shares of the company’s stock valued at $852,000 after acquiring an additional 846,297 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

NYSE:AGN traded down $0.62 on Thursday, reaching $121.65. 853,030 shares of the company’s stock were exchanged, compared to its average volume of 2,665,101. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.60. The firm has a market capitalization of $40.27 billion, a PE ratio of 7.29, a price-to-earnings-growth ratio of 1.13 and a beta of 1.39. Allergan plc has a 52-week low of $120.68 and a 52-week high of $197.00.

Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.55 by $0.24. The company had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.55 billion. Allergan had a negative net margin of 45.94% and a positive return on equity of 8.45%. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.74 earnings per share. Analysts expect that Allergan plc will post 16.68 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Tuesday, May 14th will be paid a dividend of $0.74 per share. The ex-dividend date is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a yield of 2.43%. Allergan’s dividend payout ratio (DPR) is presently 17.74%.

AGN has been the topic of several recent research reports. Bank of America set a $197.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, March 7th. Leerink Swann set a $217.00 target price on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, March 7th. Wells Fargo & Co reaffirmed a “buy” rating and issued a $189.00 target price (down previously from $202.00) on shares of Allergan in a research report on Thursday, March 7th. SunTrust Banks initiated coverage on shares of Allergan in a research report on Tuesday, March 19th. They issued a “buy” rating and a $178.00 target price on the stock. Finally, UBS Group decreased their target price on shares of Allergan from $174.00 to $173.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. Allergan has an average rating of “Hold” and a consensus target price of $175.30.

COPYRIGHT VIOLATION WARNING: “Peddock Capital Advisors LLC Grows Stake in Allergan plc (NYSE:AGN)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2019/06/13/peddock-capital-advisors-llc-grows-stake-in-allergan-plc-nyseagn.html.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Read More: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.